	US 11,834,654 B2
	Antigen binding molecules and methods of use thereof
Jed J. W. Wiltzius, Santa Monica, CA (US); and Stuart A. Sievers, Santa Monica, CA (US)
Assigned to Kite Pharma, Inc., Santa Monica, CA (US)
Filed by Kite Pharma, Inc., Santa Monica, CA (US)
Filed on Nov. 10, 2020, as Appl. No. 17/094,458.
Application 17/094,458 is a division of application No. 16/138,542, filed on Sep. 21, 2018, granted, now 10,844,371.
Claims priority of provisional application 62/562,231, filed on Sep. 22, 2017.
Prior Publication US 2021/0130808 A1, May 6, 2021
Int. Cl. C12N 15/10 (2006.01); C07K 16/00 (2006.01); A61K 47/65 (2017.01); A61K 31/37 (2006.01); C12N 15/62 (2006.01); C12N 15/85 (2006.01)

CPC C12N 15/1037 (2013.01) [A61K 31/37 (2013.01); A61K 47/65 (2017.08); C07K 16/00 (2013.01); C12N 15/1062 (2013.01); C12N 15/62 (2013.01); C12N 15/85 (2013.01); C07K 2317/34 (2013.01)]

5 Claims

1. A polynucleotide encoding a heavy chain variable region (VH) of an antigen binding molecule that specifically binds to amino acid sequence GGGS (SEQ ID NO: 1); wherein the VH comprises the nucleotide sequence of SEQ ID NO: 56, 58 or 60.